



REGIONAL ADULT PARENTERAL DRUG MONOGRAPH

GENERIC NAME
clindamycin

Effective Date: May 2013

Revised Date: March 2023

CLASSIFICATION
Antimicrobial

OTHER NAMES

PAGE

1 of 1

ADMINISTRATION POLICY:

IV Injection - *Not recommended*
 IV Infusion - May be administered by a nurse
 IM Injection- May be administered by a nurse

RECONSTITUTION/DILUTION/ADMINISTRATION:

Available as: 150 mg/mL – 2 mL and 4 mL vial,
 600 mg (12 mg/mL) and 900 mg (18 mg/mL) 50 mL premixed bags

IV Intermittent: Vial: Dilute in 50 to 100 mL normal saline. Administer over 30 to 60 minutes
 Premixed bag: Administer undiluted over 30 to 60 minutes

IM: Administer undiluted in deep IM into a large muscle.
 Not to exceed 600 mg per dose. Rotate sites.

Maximum rate: **IV Intermittent:** 30 mg per minute

Maximum concentration: **IV Intermittent:** 18 mg/mL
IM: 150 mg/mL

DOSAGE:

Usual: 600 mg to 900 mg IV every 8 hours

Maximum single dose: 900 mg (pelvic inflammatory disease or necrotizing fasciitis)

Maximum daily dose: 2700 mg

STABILITY/COMPATIBILITY:

Stability of Final Admixture: Vial: 24 hours at room temperature
 Premixed bag: Use promptly once opened. Single use only.

Compatibility: Compatible with D5W, normal saline or dextrose/saline combinations,
 Ringer’s Lactate

PRECAUTIONS, POTENTIAL ADVERSE REACTIONS:

- Gastrointestinal: diarrhea, abdominal pain, pseudomembranous colitis
- Hematologic: agranulocytosis
- Hepatic: increased liver function tests, jaundice
- Immunologic: drug reaction with eosinophilia and systemic symptoms (DRESS)